Man & Science

Man & Science is a specialist medical-device company focused on severe headache disorders rather than a broad-based medtech manufacturer. Its disclosed OCCIPITAL NERVE FIELD STIMULATION SYSTEM is designed to stimulate the occipital nerve field for chronic cluster headache, while its broader materials describe work spanning chronic migraine, cluster headache, and image-guided therapy. The company’s stated differentiators are a minimally invasive, battery-free neurostimulation design and image-guided navigation intended to target nerve bundles precisely; the website also describes an insertion procedure that can take as little as 20 minutes. Its treatment for chronic cluster headache has received U.S. FDA Breakthrough Device Designation, a regulatory signal that distinguishes the program but does not establish market approval or commercial adoption. Its relevant competitive set is likely to include developers of headache-focused neuromodulation devices and other interventional treatments, but specific names cannot be substantiated here. With an indicated employee range of 11–50 and one disclosed capital increase, Man & Science appears to be a relatively small, focused developer whose competitive case rests on targeted nerve stimulation and image-guided delivery.

Man & Science’s disclosed trajectory centers on advancing clinical and product development in targeted headache therapies. Leadership changes suggest a renewed focus on clinical execution: Hugues Wallemacq became CEO in July 2025, followed by Prof. Jean-Pierre Van Buyten’s appointment as Chief Medical Officer on May 7, 2026. Van Buyten’s stated remit covers clinical strategy and development for occipital nerve stimulation and injectable peripheral nerve stimulation programs. This appointment is an inflection point in the company’s disclosed clinical leadership, though it does not by itself confirm trial progress or regulatory milestones. The company is actively hiring across R&D, Clinical, and QA, consistent with the needs of a device developer working across engineering, clinical development, and quality functions. Its product materials describe a minimally invasive, battery-free occipital nerve field stimulation system and image-guided targeting, but no launch date, commercialization figures, or new product announcement is provided. The employee range is 11–50, while only three current leadership positions are detailed; these figures describe different scopes and do not establish a precise growth rate. Overall, the evidence points to a clinical-development-led path, with measurable future progress dependent on disclosed study, regulatory, and commercial milestones.